Disc Medicine (IRON) Return on Capital Employed (2020 - 2026)
Disc Medicine (IRON) reported Return on Capital Employed of 35.54% for Q1 2026, down 1188.0% year-over-year from 3.27% in Q1 2025, and down 2.69% on a QoQ basis from 34.61% in Q4 2025.
Disc Medicine (IRON) has 7 years of Return on Capital Employed data on file, last reported at 35.54% in Q1 2026.
- Quarterly Return on Capital Employed fell 1188.0% year-over-year to 35.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35.54% (down 1188.0% YoY) and the FY2025 annual result came in at 38.37%, down 665.0% from the prior year.
- Return on Capital Employed slipped to 35.54% in Q1 2026 per IRON's latest filing, from 34.61% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 11.21% in Q3 2022 and bottomed at 36.37% in Q4 2022.
- The 5-year median for Return on Capital Employed is 26.17% (2024), against an average of 26.49%.
- The widest annual swing landed in 2022, when Return on Capital Employed surged 2321 bps; it then sank 1188 bps in 2026.
- Tracing IRON's Return on Capital Employed over 5 years: stood at 36.37% in 2022, then climbed by 29 bps to 25.98% in 2023, then dropped by 6 bps to 27.45% in 2024, then slipped by 26 bps to 34.61% in 2025, then slipped by 3 bps to 35.54% in 2026.
- Per Business Quant, the three latest IRON Return on Capital Employed figures stand at 35.54% (Q1 2026), 34.61% (Q4 2025), and 32.79% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | -35.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.54% |
| Dec 31, 2025 | -34.61% |
| Sep 30, 2025 | -32.79% |
| Jun 30, 2025 | -25.32% |
| Mar 31, 2025 | -23.65% |
| Dec 31, 2024 | -27.45% |
| Sep 30, 2024 | -26.17% |
| Jun 30, 2024 | -26.95% |
| Mar 31, 2024 | -28.15% |
| Dec 31, 2023 | -25.98% |
| Sep 30, 2023 | -20.89% |
| Jun 30, 2023 | -22.33% |
| Mar 31, 2023 | -29.55% |
| Dec 31, 2022 | -36.37% |
| Sep 30, 2022 | -11.21% |
| Jun 30, 2022 | -17.89% |
| Mar 31, 2022 | -25.51% |
| Dec 31, 2021 | -27.98% |
| Sep 30, 2021 | -34.42% |
| Jun 30, 2021 | -24.54% |
| Mar 31, 2021 | -37.52% |
| Dec 31, 2020 | -61.94% |